Male sex (%)
|
80.8
|
69.9
|
54.9
|
68.6
|
<0.001
|
Age (yr)
|
59.1 ± 14.9
|
63.7 ± 14.3
|
68.3 ± 13.2
|
63.7 ± 1.46
|
<0.001
|
Indication for cardiac surgeryc
| | | | | |
Valvulopathy (%)
|
72.5
|
69.2
|
68.7
|
70.1
|
0.561
|
Coronary artery disease (%)
|
34.5
|
40.9
|
37.7
|
37.7
|
0.285
|
Aortic disease (%)
|
35.2
|
28.0
|
23.2
|
28.8
|
0.006
|
Mean arterial blood pressure (mmHg)
|
94 ± 30
|
90 ± 36
|
82 ± 38
|
89 ± 35
|
<0.001
|
Sinus rhythm (%)
|
92.3
|
84.6
|
76.8
|
84.6
|
<0.001
|
Diabetes mellitus (%)
|
14.6
|
26.1
|
35.4
|
24.8
|
<0.001
|
Coronary artery disease (%)
|
36.2
|
45.5
|
47.2
|
42.9
|
0.018
|
Chronic cardiac failure (%)
|
90.2
|
85.7
|
83.1
|
86.3
|
0.042
|
Ejection fraction (%)
|
50 ± 27
|
49 ± 25
|
48 ± 26
|
49 ± 26
|
0.542
|
EuroSCORE II
|
2.6 (1.4 to 5.2)
|
3.7 (2.0 to 6.8)
|
5.7 (2.7 to 12.4)
|
3.8 (1.9 to 7.4)
|
<0.001
|
FGF23 (RU/ml)
|
39.2 (31.7 to 45.4)
|
64.5 (56.5 to 75.3)
|
182.9 (114.5 to 416.5)
|
64.5 (45.4 to 114.5)
|
<0.001
|
Serum creatinine (mg/dl)
|
0.98 ± 0.20
|
1.06 ± 0.26
|
1.53 ± 1.35
|
1.19 ± 0.84
|
<0.001
|
Serum NT-proBNP (pg/ml)
|
212 (90 to 612)
|
572 (170 to 1,415)
|
1,276 (443 to 3,575)
|
525 (156 to 1,507)
|
<0.001
|
Serum hsCRP (mg/L)
|
1.6 (0.7 to 4.5)
|
2.4 (0.9 to 6.1)
|
5.2 (2.1 to 16.3)
|
2.6 (1.0 to 8.1)
|
<0.001
|
Duration of surgery (min)
|
156 ± 43
|
171 ± 55
|
185 ± 67
|
171 ± 57
|
<0.001
|
Duration of cardiopulmonary bypass (min)
|
75 ± 32
|
80 ± 36
|
92 ± 48
|
82 ± 40
|
<0.001
|
Time of hypothermic circulatory arrest (min)
|
51 ± 22
|
51 ± 24
|
58 ± 34
|
53 ± 27
|
0.001
|
Ventilation time (hr)
|
9 (8 to 13)
|
11 (8 to 16)
|
14 (10 to 29)
|
11 (8 to 18)
|
<0.001
|
Length of ICU stay (days)
|
1 (1 to 1)
|
1 (1 to 1)
|
1 (1 to 3)
|
1 (1 to 2)
|
<0.001
|
Total length of stay (days)
|
9 (8 to 11)
|
10 (9 to 12)
|
11 (9 to 16)
|
10 (8 to 13)
|
<0.001
|
Acute kidney injury (%)
|
11.8
|
23.1
|
45.8
|
26.8
|
<0.001
|
Non-occlusive mesenteric ischaemia (%)
|
3.8
|
6.6
|
16.5
|
9.0
|
<0.001
|
Death during hospitalisation (%)
|
0.0
|
2.1
|
6.7
|
2.9
|
<0.001
|
Death during follow-up (%)
|
3.1
|
5.6
|
12.2
|
7.0
|
<0.001
|